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Activation of the Thromboxane A2 Receptor by
8-Isoprostane Inhibits the Pro-Angiogenic Effect of
Vascular Endothelial Growth Factor in Scleroderma
Pei-Suen Tsou1,2, M. Asif Amin2, Phillip L. Campbell2, George Zakhem2, Beatrix Balogh2, Gautam Edhayan2,
Ray A. Ohara2, Elena Schiopu1,2, Dinesh Khanna1,2, Alisa E. Koch2,3 and David A. Fox1,2
The pathogenesis of scleroderma (SSc) includes components of autoimmunity, vascular dysfunction, and
accumulation of extracellular matrix. 8-isoprostane, an oxidized lipid created by oxidative stress, activates the
thromboxane A2 receptor (TXAR) and the Rho-associated kinase (ROCK) pathway. In this study, we determined
whether the TXAR was activated by 8-isoprostane in SSc endothelial cells (ECs) and whether this pathway
inhibited VEGF-induced angiogenesis. Elevated 8-isoprostane was observed in plasma and conditioned media
from SSc patients. SSc-conditioned media inhibited EC tube formation, whereas addition of vitamin E, by
reducing 8-isoprostane, increased tube formation. VEGF did not induce angiogenesis in SSc ECs, but vitamin E or
TXAR inhibition restored its effect. The expression of TXAR, RhoA, and ROCK1/2 was elevated in SSc ECs. ROCK
activity and 8-isoprostane-induced ROCK activation were signiﬁcantly higher in SSc ECs, whereas VEGF had no
effect. The hyper-activation of the TXAR leads to inhibition of VEGF-induced angiogenesis, as inhibition of the
TXAR pathway results in a blockade of 8-isoprostane-induced ROCK activation and restoration of VEGF activity.
These results suggest that the TXAR pathway has a crucial role in angiogenesis and that 8-isoprostane is not just a
by-product of oxidative stress but also has a signiﬁcant role in the impaired angiogenesis that characterizes SSc.
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INTRODUCTION
Systemic sclerosis (scleroderma (SSc)) is a devastating disease
that involves autoimmunity, progressive ﬁbrosis of internal
organs, and vascular damage. Although the etiology of SSc is
currently unknown, it is clear that vascular morphological
changes appear before the onset of ﬁbrosis. The loss of
vasculature results in tissue hypoxia, which normally
promotes angiogenesis through the production of
pro-angiogenic factors. Among those, vascular endothelial
growth factor (VEGF) is a major trigger of the angiogenic
process and exempliﬁes the paradox of SSc dysregulated
angiogenesis. Thus, despite signiﬁcant elevation of VEGF,
adaptive angiogenesis is absent, and the disease is shifted
toward a progressive loss of capillaries. Moreover, VEGF
expression is elevated in various cell types in SSC skin
(Mackiewicz et al., 2002; Distler et al., 2004; Davies et al.,
2006), in addition to increased circulating VEGF levels
(Distler et al., 2002; Kuryliszyn-Moskal et al., 2005;
Hummers et al., 2009). The cellular mechanisms of how
angiogenesis becomes dysregulated in the presence of
elevated VEGF in SSc are still not known.
Oxidative stress occurs when there is an imbalance
between free radical production and antioxidative capacity
of the biological system. During this process, lipids are
oxidized by reactive oxygen species resulting in the formation
of various peroxidation products. One class of oxidized lipids
in abundance is the isoprostanes. They are a series of
prostaglandin isomers produced independently of cycloox-
ygenase as products of free radical-catalyzed lipid peroxida-
tion and are sensitive indicators for oxidative injury (Morrow,
2000). In addition to being a biomarker, 8-isoprostane is a
mediator of important biological effects (Comporti et al.,
2008; Roberts and Milne, 2009). It is a potent vasoconstrictor
in a variety of vascular beds and induces endothelin release,
proliferation of smooth muscle cells, and inhibition of
angiogenesis through the thromboxane A2 receptor (TXAR;
Morrow, 2000; Hou et al., 2004). Inﬂammatory effects of
8-isoprostane have also been described. 8-isoprostane
suppressed monocyte attachment to endothelial cells (ECs)
via TXAR activation (Kumar et al., 2005). In addition, it
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increased IL-8/CXCL8 and macrophage inﬂammatory protein-
1α/CCL3 expression in human macrophages through
extracellular signal–regulated kinase1/2 and P38 pathways
(Scholz et al., 2003). In SSc, elevated 8-isoprostane levels
have been found in blood (Stein et al., 1996; Ogawa et al.,
2006), urine (Avouac et al., 2010), bronchoalveolar lavage
(Montuschi et al., 1998), and exhaled breath (Tufvesson et al.,
2010) of SSc patients.
When 8-isoprostane activates the TXAR, this G-protein
coupled receptor in turn activates the GTPase Ras homolog
gene family-member A (RhoA), which is critical for dynamic
changes in cell shape and adhesion that govern polarity and
drive migration (Nobes and Hall, 1999). Activation of TXAR
switches RhoA from an inactive, GDP-bound form to an
active GTP-bound form that subsequently activates target
molecules. The effect of RhoA is carried out by the
downstream Rho-associated kinases (ROCK), which include
the 2 isoforms ROCK1 and ROCK2. Activation of TXAR
mediates a persistent activation of RhoA, which in turn affects
actin ﬁlament assembly and contractility. Therefore, RhoA
and ROCK are known to have a critical role in EC motility by
regulating the formation of F-actin stress ﬁbers and focal
adhesion turnover (Lamalice et al., 2007). Persistent ROCK
activity may inhibit EC motility by increasing cell adhesion to
the substratum or by slowing down turnover of focal
adhesions (Wojciak-Stothard et al., 2007). Interestingly, VEGF
transiently activates RhoA/ROCK to initiate focal adhesion
turnover, which promotes angiogenesis (Lamalice et al., 2007).
Microvascular ECs are key players in SSc microangiopathy,
and they have been examined by us and others as useful
models for studying dysregulated angiogenesis (Manetti et al.,
2011; Rabquer et al., 2011; Tsou et al., 2012a; Giusti et al.,
2013). In the pathogenesis of SSc, increased oxidative
damage has been implicated (Bruckdorfer et al., 1995; Stein
et al., 1996; Sambo et al., 2001; Svegliati et al., 2005;
Servettaz et al., 2007; Tsou et al., 2012b; Tsou et al., 2014).
However, the role of oxidative stress in SSc vasculopathy has
not been elucidated. In this study, we examined the
mechanism of impaired angiogenesis in SSc ECs and
focused on the interplay between 8-isoprostane/TXAR and
VEGF signaling, thus providing a possible link between
oxidative stress and vasculopathy in SSc.
RESULTS
Oxidative stress in SSc
To evaluate whether oxidative stress is observed in SSc, we
measured 8-isoprostane in patient’s blood. Plasma 8-
isoprostane levels were signiﬁcantly elevated in SSc patients,
speciﬁcally diffuse SSc patients, as well as patients with
interstitial lung disease (Figure 1a). In ECs isolated from diffuse
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Figure 1. Elevation of 8-isoprostane and oxidative stress in diffuse scleroderma (dSSc). (a) Plasma 8-isoprostane was measured using an 8-isoprostane EIA kit
(Cayman Chemical, Ann Arbor, MI). Plasma 8-isoprostane was elevated in patients with diffuse SSc or interstitial lung disease but not in patients with limited SSc
or pulmonary hypertension. (b) Superoxide production was examined by DHE staining. The nuclei were stained using DAPI. Superoxide production was
increased in SSc ECs compared with normal ECs. (c) 8-isoprostane levels were measured using an 8-isoprostane EIA kit and were elevated in SSc EC culture media
compared with normal EC culture media. 8-Isoprostane levels were reduced by vitamin E in both normal and SSc EC culture media. Means are shown as
mean± SD. Differences were determined using Student’s t-test, and P-valueso0.05 were signiﬁcant. Scale bar= 50 μm. dSSc, diffuse SSc; EC, endothelial cell;
ILD, interstitial lung disease; lSSc, limited SSc; n, number of patient; NS, not-stimualted; PAH, pulmonary hypertension; SSc, scleroderma; VEGF, vascular
endothelial growth factor; VitE, vitamin E.
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SSc patients, increased superoxide was observed (Figure 1b).
The cells were of EC origin as indicated by the positive
staining of von Willebrand factor. SSc ECs released signiﬁ-
cantly more 8-isoprostane into the culture media than healthy
ECs, and stimulation with VEGF had no effect on
8-isoprostane production (Figure 1c). Vitamin E, an antiox-
idant that decreases 8-isoprostane in hypercholesterolemic
patients (Davi et al., 1997), signiﬁcantly reduced
8-isoprostane released from both normal and SSc ECs.
Matrigel tube formation
As increased 8-isoprostane levels were observed in
SSc-EC-conditioned media (Figure 1c), we examined whether
conditioned media from SSc ECs had an inhibitory effect on
EC tube formation. Conditioned media alone from
healthy ECs induced healthy ECs to form tubes when
they were plated on Matrigel (Figures 2a and b, and
Supplementary ﬁgure 1 online). VEGF increased the formation
of tubes, and co-incubation of VEGF and vitamin E further
increased tube formation. In contrast, conditioned media from
SSc ECs induced fewer healthy ECs to form tubes. Addition of
VEGF increased tube formation, but the extent was signiﬁ-
cantly lower than that observed with healthy EC-conditioned
media. Addition of vitamin E with VEGF increased tube
formation signiﬁcantly. To test whether vitamin E has an effect
on SSc ECs, we performed a Matrigel tube formation assay
using SSc ECs (Figure 2c). Addition of vitamin E, alone or in
combination with VEGF, increased the amount tubes formed.
In vitro chemotaxis
To more speciﬁcally examine the effect of 8-isoprostane on
VEGF-induced cell migration, we performed chemotaxis
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Figure 2. Vitamin E reversed defection endothelial tube formation by scleroderma (SSc) endothelial cells (ECs). (a) To assess the effect of conditioned media
from normal or SSc ECs on angiogenesis, Matrigel tube formation assay was performed. Representative Matrigel tube formation photomicrographs show that
culturing normal ECs with conditioned media from normal ECs resulted in spontaneous tube formation and that addition of VEGF (1 ng ml−1) further increased
tube formation. In contrast, incubating normal ECs with conditioned media from SSc ECs did not induce spontaneous tube formation, and addition of VEGF had
no effect. The presence of vitamin E (50 μM) increased tube formation in both normal and SSc-EC-conditioned media. (b) The number of branching points was
quantiﬁed and graphed. (c) Tube formation assay using SSc ECs. Vitamin E increased the ability of SSc ECs to form tubes, whether used alone or with VEGF.
Means are shown mean± SD. Differences were determined using two-way ANOVA, and P-valueso0.05 were signiﬁcant. Scale bar=200 μm. ANOVA, analysis
of variance; CM, conditioned media; n, number of patient; NS, not-stimualted; SSc, scleroderma; VEGF, vascular endothelial growth factor; VitE, vitamin E.
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assays. We ﬁrst examined whether SSc ECs respond toward
VEGF. VEGF dose-dependently induced EC migration in
normal ECs, but this was markedly attenuated in SSc
ECs (Figure 3a). We next examined whether 8-isoprostane
had an effect on VEGF-induced cell migration. Again normal
ECs migrated toward VEGF as shown in Figure 3b
(VEGF 1 ngml− 1 vs. phosphate-buffered saline group).
8-isoprostane signiﬁcantly inhibited the ability of VEGF to
induce migration of ECs. To determine whether 8-isoprostane
exerted its inhibitory effect through the TXAR and its
downstream ROCK pathway, a TXAR inhibitor (SQ29548) or
a ROCK inhibitor (Y27632) was added. The addition of the
inhibitor together with VEGF and 8-isoprostane allowed
signiﬁcant EC migration. In contrast to normal ECs, VEGF
failed to induce SSc EC migration (Figure 3b). However, this
was restored partially by the addition of the inhibitors,
although the extent of migration was signiﬁcantly less
compared with healthy ECs. These results suggest that the
TXAR pathway is in part responsible for the impaired
angiogenic response to VEGF in SSc.
We further explored the role of TXAR in VEGF-induced
angiogenesis by knocking down TXAR expression. In normal
ECs, cells treated with control siRNA migrated toward VEGF
signiﬁcantly compared with phosphate-buffered saline,
whereas addition of 8-isoprostane inhibited the effect of
VEGF (Figure 3c). When TXAR was knocked down, the
inhibitory effect of 8-isoprostane on VEGF-induced cell
migration was no longer apparent. SSc ECs, when treated
with control siRNA, were unresponsive toward VEGF alone
and in combination with 8-isoprostane. However, when
TXAR was knocked down, as 8-isoprostane could not act on
TXAR, VEGF was able to induce migration of SSc ECs,
whether acting alone or in combination with 8-isoprostane.
Phosphorylation of focal adhesion kinase
As RhoA and ROCK are key players in EC motility by
regulating focal adhesion turnover (Lamalice et al., 2007), and
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Figure 3. Role of the thromboxane A2 receptor (TXAR) in impaired angiogenesis in scleroderma (SSc) endothelial cells (ECs). (a) Chemotaxis assays were
performed to examine whether VEGF could dose-dependently induce cell migration in normal and SSc ECs. Normal ECs migrated toward VEGF at both 1 and
50 ngml−1 VEGF, whereas SSc ECs only responded at the higher dose. (b) Chemotaxis assays were performed to determine the involvement of TXAR and its
downstream pathway in 8-isoprostane- and VEGF-induced angiogenesis in both normal and SSc ECs. In normal ECs, VEGF induced signiﬁcant cell migration
compared with its control PBS, whereas 8-isoprostane inhibited it. The co-incubation of either TXAR or ROCK inhibitor signiﬁcantly restored VEGF-induced
migration in the presence of 8-isoprostane. In SSc ECs, VEGF did not induce cell migration. The addition of the inhibitors signiﬁcantly restored VEGF’s ability to
move cells; however, the extent of migration was not as great as that seen in normal ECs. (c) To further examine the role of the TXAR in VEGF-induced
angiogenesis in SSc, the TXAR was knocked down and chemotaxis was performed. In both normal and SSc ECs, knocking down the TXAR restored the ability of
VEGF to induce cell migration in the presence of 8-isoprostane. Results are expressed as mean± SD, and Po0.05 is considered signiﬁcant. HPF, high power ﬁeld;
8-iso, 8-isoprostane; n, number of experiment; PBS, phosphate-buffered saline; RhoA, Ras homolog gene family-member A; ROCK, Rho-associated kinase; SSc,
scleroderma; SQ, SQ29548 TXAR inhibitor; TXAR, thromboxane A2 receptor; VEGF, vascular endothelial growth factor; Y, Y27632 ROCK inhibitor.
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as focal adhesion kinase (FAK) is phosphorylated as a result of
stimulation of the VEGF pathway during focal adhesion
activation, we examined the extent of FAK phosphorylation
in both normal and SSc ECs in relation to the expression
of TXAR. In normal ECs, VEGF induced signiﬁcant
phosphorylation of FAK, which was inhibited by
8-isoprostane when cells were transfected with control siRNA
(Figure 4a). When TXAR was knocked down, the extent of
FAK phosphorylation increased signiﬁcantly in the VEGF+8-
isoprostane group. In SSc ECs, VEGF failed to increase FAK
phosphorylation. When TXAR was knocked down, surpris-
ingly the basal FAK phosphorylation levels decreased
signiﬁcantly. However, when cells were treated with either
VEGF or VEGF and 8-isoprostane together, signiﬁcant
phosphorylation of FAK was observed, although the extent
was signiﬁcantly lower compared with normal ECs.
Expression of the TXAR pathway
To examine whether the expression of the TXAR and its
downstream signaling pathway differs between healthy and
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Figure 4. Defective phosphorylation of focal adhesion kinase (FAK) in scleroderma (SSc) endothelial cells (ECs). (a) Phosphorylation of FAK was examined by
western blotting. In normal ECs, VEGF induced signiﬁcant FAK phosphorylation, whereas in the presence of 8-isoprostane the phosphorylation was inhibited.
When the TXAR was knocked down, the inhibitory effect of 8-isoprostane disappeared. In SSc ECs, VEGF failed to induce FAK phosphorylation in the absence or
presence of 8-isoprostane. When the TXAR was knocked down, the basal levels of FAK phosphorylation decreased, whereas VEGF and VEGF plus 8-isoprostane
groups signiﬁcantly increased FAK phosphorylation. The extent was still signiﬁcantly lower compared with the normal ECs. (b–e) The expression of the TXAR,
ROCK1/2, and RhoA was examined by qPCR and western blotting. (b) Differences in the TXAR expression did not reach a statistical signiﬁcance at either mRNA
or protein levels. (c) The expression of ROCK1 was discordant between mRNA and protein levels. ROCK1 protein was signiﬁcantly higher in SSc ECs. (d) Similar
to ROCK1, ROCK2 protein expression was signiﬁcantly higher in SSc ECs. (e) Both protein and mRNA levels of RhoA were elevated in SSc ECs compared with
normal. Results are expressed as mean± SD, and Po0.05 is considered signiﬁcant. FAK, focal adhesion kinase; 8-iso, 8-isoprostane; n, number of subject; qPCR,
quantitative PCR; RhoA, Ras homolog gene family-member A; ROCK, Rho-associated kinase; TXAR, thromboxane A2 receptor; VEGF, vascular endothelial
growth factor.
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SSc ECs, we performed quantitative PCR and western blotting.
Although there was a trend toward decreased TXAR mRNA
and increased TXAR protein levels in SSc ECs, the variability
rendered it not statistically signiﬁcant (Figure 4b). ROCK1
mRNA expression was signiﬁcantly elevated in normal ECs
compared with SSc ECs (Figure 4c); however, the protein
expression was signiﬁcantly elevated in SSc ECs. Similar
results were observed for ROCK2. ROCK2 mRNA expression
in normal ECs was higher, but protein expression was lower
(Figure 4d). The discrepancy between the mRNA and
protein levels could be due to differences in post-transcrip-
tional/translational modiﬁcations and/or RNA and protein
stability. It is possible that the lower ROCK mRNA levels in
SSc ECs were due to a shorter mRNA half-life. In addition,
the timing of the translation and transcription process
is likely to differ. We collected the cells after 24 hours of
stimulation, and it is possible that peak mRNA production
occurred at an earlier time point. RhoA mRNA
was signiﬁcantly higher in SSc ECs when they were
stimulated with 8-isoprostane or VEGF (Figure 4e). At the
protein level, RhoA was signiﬁcantly higher in SSc ECs
under basal conditions, as well as after 8-isoprostane
stimulation.
ROCK activity in ECs
To further examine the involvement of the ROCK pathway in
ECs, ROCK activity was determined after 8-isoprostane or
VEGF stimulation at different time points. Under basal
conditions, higher ROCK activity was observed in SSc ECs
compared with healthy ECs (Figure 5a). This could be
attributed to the higher expression levels of ROCK1/2 in SSc
ECs as seen in Figures 4c and d. When stimulated with
8-isoprostane, both normal and SSc ECs showed signiﬁcantly
elevated ROCK activity at 5 and 15minutes (Figure 5b). At
both time points, ROCK activity was signiﬁcantly higher in
SSc ECs compared with normal ones. On the other hand,
VEGF induced a signiﬁcant increase in ROCK activity in
normal ECs at 5 minutes, and it returned to baseline at 15
minutes. In contrast, VEGF failed to induce ROCK activation
in SSc ECs (Figure 5c). Taken together, these ﬁndings conﬁrm
that the VEGF receptor and its downstream ROCK signaling
pathway function aberrantly in SSc ECs and that 8-isoprostane
stimulation results in enhanced ROCK activation, more so in
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Inhibition or knockdown of the TXAR pathway restores the ability of SSc ECs to migrate toward VEGF, suggesting that the TXAR has a critical role in VEGF-
induced angiogenesis in SSc. FAK, focal adhesion kinase; 8-iso, 8-isoprostane; n, number of subjects; RhoA, Ras homolog gene family-member A; VEGF, vascular
endothelial growth factor.
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SSc ECs than in normal ECs. To further examine whether
8-isoprostane signals through the TXAR and the ROCK
pathway, we knocked down TXAR and measured
8-isoprostane-activated ROCK levels. Although 8-
isoprostane increased ROCK activity in control siRNA–
transfected SSc ECs, it failed to activate ROCK in TXAR
knockdown cells (Figure 5d).
DISCUSSION
In this study, we determined that oxidative stress contributes
to dysregulated angiogenesis in SSc skin ECs. As summarized
in Figure 5e, we ﬁrst established that increased 8-isoprostane
levels are observed in SSc and that vitamin E not only
decreases 8-isoprostane but also increases tube formation by
both normal and SSc ECs. We then determined that
8-isoprostane affects VEGF-induced angiogenesis by applying
chemical inhibitors or siRNA to block the TXAR pathway.
Finally, we showed that the expression of TXAR and
RhoA/ROCKs is elevated and that the 8-isoprostane-induced
ROCK pathway is hyperactivated in SSc ECs compared with
normals. The direct link between 8-isoprostane, TXAR, and
the ROCK pathway was further supported by the effects of
knocking down TXAR expression. These results provide a
potential link between oxidative stress and impaired angio-
genesis in SSc through the effect of 8-isoprostane on
VEGF-induced angiogenesis.
The VEGF paradox in SSc vascular deﬁciency has been
well documented. Several studies have been conducted to
delineate the possible mechanism. Giusti et al. (2005) showed
that the expression of pro-angiogenic kallikrein 12 was
decreased in SSc patients. Kallikrein 12 is involved in
VEGF-mediated angiogenesis, and therefore a decrease in its
expression leads to diminished VEGF response. In a recent
report, an increase in a splice variant of VEGF, VEGF165b, in
SSc has been observed (Manetti et al., 2011). VEGF165b, in
contrast to other splice variants of VEGF, is anti-angiogenic.
The authors elegantly showed that recombinant VEGF165b
and SSc-EC-conditioned medium inhibited VEGF-mediated
VEGF receptor phosphorylation and capillary morphogenesis
in healthy ECs. In addition, anti-VEGF165b blocking anti-
bodies abrogated the anti-angiogenic effect of SSc-EC-
conditioned medium. Our data suggesting that 8-isoprostane
inhibits VEGF-mediated angiogenesis add to the mechanisms
of the VEGF paradox in SSc. Although the relative contribu-
tion of each pathway is difﬁcult to delineate, it appears that
the VEGF paradox comprised several factors that lead to
failure of angiogenesis.
We showed that elevated plasma levels of 8-isoprostane
were seen only in diffuse patients but not in limited patients,
which was in agreement with the study by Tufvesson et al.
(2010). This suggests that oxidative stress is more prominent in
patients with more extensive SSc. However, in a Japanese
study, there was no difference between diffuse and limited
patients (Ogawa et al., 2006). This might be due to racial or
regional differences. In that study, the authors also showed
that 8-isoprostane is associated with the severity of lung
ﬁbrosis and the extent of vascular damage. It is interesting that
we observed elevated 8-isoprostane levels in patients with
interstitial lung disease but not in those with PAH (Figure 1a).
As diffuse SSc patients are often afﬂicted with interstitial lung
disease and limited SSc patients develop PAH, the results
seem to correspond well with the disease phenotype.
In this study, 8-isoprostane inhibited VEGF-induced
angiogenesis by the TXAR activation, as the TXAR antagonist
SQ29548 reversed 8-isoprostane-induced inhibition of cell
migration and focal adhesion in both normal and SSc ECs. In
addition, by knocking down the TXAR, the inhibitory effect of
8-isoprostane in SSc ECs was also reversed, in the context of
the inability to activate the ROCK pathway. These ﬁndings
agree with several studies showing that TXAR is
anti-angiogenic (Gao et al., 2000; Ashton and Ware, 2004;
Benndorf et al., 2008). However, the role of the TXAR in
angiogenesis is not quite clear, as conﬂicting reports exist.
Thromboxane A2, a ligand of TXAR, can function as a critical
intermediary of angiogenesis (Daniel et al., 1999; Nie et al.,
2000). In addition, TXAR stimulation enhanced ICAM-1 and
vascular cell adhesion molecule-1 expression in human
umbilical vein endothelial cells (Ishizuka et al., 1998). In
contrast, there are reports suggesting that TXAR stimulation
inhibits EC migration and in vitro capillary formation (Ashton
et al., 1999), and it induces apoptosis of ECs (Gao et al.,
2000). Moreover, activation of TXAR limits angiogenesis by
inhibiting VEGF signaling and antagonizing the pro-
angiogenic effects of basic ﬁbroblast growth factor (Ashton
et al., 2004; Ashton and Ware, 2004); both pathways are
inactivated in SSc. The discrepancies between these studies
might be due to the size of the vasculature from which the ECs
are isolated; TXAR activation tends to be pro-angiogenic using
ECs isolated from larger vessels, such as human umbilical vein
endothelial cells, and anti-angiogenic on ECs from micro-
vascular structures, which were used in our study. None-
theless, we were able to show that TXAR protein expression is
increased in SSc ECs and that inhibition of this receptor blocks
the effect of 8-isoprostane and increases the effect of
VEGF-induced cell migration, tube formation, and focal
adhesion activation. The increased expression of the TXAR
and its downstream RhoA/ROCK pathway skews the SSc ECs
to an anti-angiogenic state by hyperactivating this pathway,
overpowering the transiently activated VEGF-ROCK pathway,
and diminishing the pro-angiogenic effect of VEGF.
The ability of both VEGF and 8-isoprostane to stimulate the
ROCK pathway in ECs and result in opposite functions seems
counterintuitive. We postulate that the difference in the
activation time course skews the cells to different pathways
downstream of ROCK, governing the fate of the ECs to
become pro-angiogenic or anti-angiogenic. As shown in
Figure 5, VEGF transiently activated the ROCK pathway as
8-isoprostane stimulated ROCK activation for a longer period
of time. Our data agree with the study performed by Benndorf
et al. (2008), where they showed brief activation of RhoA by
VEGF alone and prolonged activation when 8-isoprostane
was added. Although basal levels of RhoA/ROCK are essential
for cell migration, its activation could also lead to inhibition of
cell movement (Tkach et al., 2005). It has been shown that
prolonged activation of RhoA/ROCK leads to EC motility
inhibition due to increased adhesion to the substratum
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(Wojciak-Stothard et al., 2007). Therefore, the pronounced
and prolonged activation of the ROCK pathway in SSc ECs
becomes the dominate pathway and gears the cells to an
anti-angiogenic state. Another interesting ﬁnding is that VEGF
failed to induce ROCK activation in SSc ECs (Figure 5c). The
mechanism is not known; however, it is possible that this is a
result of a dysfunctional VEGF receptor (VEGFR2) as it has
been shown that, although its expression is increased in SSc
ECs, its ability to be phosphorylated is impaired (Manetti
et al., 2011). The machinery of the VEGF pathway in SSc EC
requires further investigation. It should be noted that the TXAR
pathway not only affects the ROCK pathway, as shown in our
study, it also affects other signaling pathways induced by
VEGF, including AKT, endothelial nitric oxide synthase, as
well as protein kinase D1 (Ashton and Ware, 2004).
Interestingly, we previously showed that, in SSc ECs, the
AKT pathway is impaired when stimulated with various
chemokines (Tsou et al., 2012a). It is possible that the 8-
isoprostane/TXAR pathway affects both ROCK and AKT
pathways in SSc and therefore inhibits the ability of ECs to
migrate.
In summary, this study provides a better understanding of
the impact of excess oxidative stress in SSc dysregulated
angiogenesis. We successfully showed that (i) the TXAR and
the RhoA/ROCKs are upregulated in SSc ECs; (ii) the
VEGF-induced ROCK pathway is impaired; (iii) it adds to
the mechanism of the VEGF paradox that the TXAR pathway
has an inhibitory role in VEGF-induced angiogenesis;
(iv) elevated 8-isoprostanes in SSc is not just a marker for
oxidative stress, they in fact have biological relevance
in the pathogenesis of SSc. This study provides not only a
molecular mechanism to explain dysregulated angiogenesis
in SSc but also insights that can potentially be
applied to other diseases that are affected by oxidative
stress.
See Supplementary File online for more Discussion.
MATERIALS AND METHODS
The detailed Materials and Methods section can be found in the
Supplementary document online.
Patients
All SSc patients fulﬁlled the 1980 American College of Rheumatology
criteria for classiﬁcation of SSc (LeRoy, 1974). The details of the
enrolled subject’s characteristics are summarized in Table 1. For EC
isolation, skin biopsies from healthy volunteers and diffuse SSc
patients were obtained. Two 4-mm punch biopsies were taken from
the distal forearm of healthy subjects or from involved skin of SSc
patients. A written informed consent was obtained from all subjects,
and the study was approved by the Institutional Review Board of the
University of Michigan.
Cell culture
Dermal ECs were isolated from human skin in our laboratory. The
biopsies were cut into small pieces and digested for 30minutes in a
solution containing 2.4 units ml−1 dispase (Invitrogen, Grand Island,
NY), 650 units ml−1 type II collagenase (Sigma Aldrich, St Louis,
MO), and 10,000 Dornase units ml−1 DNase (Millipore, Billerica,
MA). After digestion, the cells were cultured in EBM-2 medium with
growth factors (Lonza, Allendale, NJ). Dermal ECs were isolated
using the CD31 MicroBead Kit and a MiniMACS Separator with an
MS Column (Miltenyi Biotech, San Diego, CA). ECs, which were the
positively selected cells, were maintained in EBM-2 medium with
growth factors on gelatin-coated plates. If needed, the cells were re-
puriﬁed when the cultures were expanded. Passages 3–6 were used
for experiments, and the purity of the cells was ~ 95%. Two days
before experiments, ECs were grown in EBM basal media in the
presence of bovine brain extract, epidermal growth factor, as well as
5% fetal bovine serum to minimize the effect of growth factors in
complete EBM-2 media. ECs were serum starved in EBM-2 basal
media in the presence of 0.2% fetal bovine serum overnight before
stimulation experiments. To collect conditioned media, conﬂuent
ECs were washed and incubated overnight with EBM-2 basal
medium with 0.2% fetal bovine serum for 24 hours. The culture
supernatants were collected, centrifuged, and stored at − 80°C until
use. The ECs used in this study were isolated from 23 patients with
diffuse SSc and 19 healthy subjects.
Statistical analysis
Results were expressed as mean± SD, except for Figure 1a, where it
is presented as median± interquartile range. To determine the
differences between the groups, Student’s t-test, Mann–Whitney's
U-test, or two-way analysis of variance was performed. P-values of
Table 1. Characteristics of SSc patients and healthy
volunteer subjects
SSc (n= 61)
Diffuse SSc
(n=44)
Limited
SSc
(n=17)
Healthy
subjects
(n=33)
Age (years) 55.0± 1.51 53.9±1.8 57.6±2.7 45.3±2.5
Sex F53/M8 F38/M6 F15/M2 F20/M13
Disease duration
(years)
7.1± 1.1 4.5±0.6 13.5±3.0 NA
mRSS (0–51) 15.0± 1.5 19.0±1.8 4.8±0.8 NA
Raynaud’s 60 43 17 NA
Early disease2 36 30 6 NA
Deceased 5 3 2 NA
History of digital
ulcers
18 14 4 NA
Teleangectasias 34 24 10 NA
Gastrointestinal
disease
51 36 15 NA
ILD 30 24 6 NA
PAH3 12 9 3 NA
Renal
involvement
2 2 0 NA
Abbreviations: F, female; ILD, interstitial lung disease; M, male; mRSS,
modiﬁed Rodnan skin score; NA, not applicable; PAH, pulmonary arterial
hypertension; SSc, scleroderma.
1Mean± SEM.
2Less than 5 years.
3Mean pulmonary artery pressure at rest⩾25mmHg; pulmonary capillary
wedge pressure⩽ 15mmHg.
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less than 0.05 with two-tailed analysis were considered statistically
signiﬁcant.
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